Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Liposarcoma, Myxoid 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Chondrosarcoma 1

Interventions

Gemcitabine 3Docetaxel 3belinostat 2Fluorouracil 2Bevacizumab 2venetoclax 1toripalimab 1tanespimycin 1ivosidenib 1itacitinib 1durvalumab 1capivasertib 1birinapant 1baricitinib 1Zoledronic Acid 1Thalidomide 1Taxes 1Radiotherapy 1Paclitaxel 1Medicare Part B 1Leucovorin 1Irinotecan 1Immunoglobulin G 1INCB039110 1IFL protocol 1Filgrastim 1Disulfides 1Cisplatin 1Chemotherapy, Adjuvant 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Chondrosarcoma × baricitinib × Clear all
NCT03670069 2024-05-08

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Fred Hutchinson Cancer Center

Phase 1 Terminated
27 enrolled
Sarcoma

Chondrosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡